Urinary Tract Infection Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented Drug (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans, and Other Drugs), By Indication (Complicated UTI, Uncomplicated UTI, and Other Indications), and By Region, Competition 2018-2028
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUrinary Tract Infection Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented Drug (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans, and Other Drugs), By Indication (Complicated UTI, Uncomplicated UTI, and Other Indications), and By Region, Competition 2018-2028
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD 7.20 billion |
| CAGR (2024-2028) | 3.12% |
| Fastest Growing Segment | Penicillin and Combinations |
| Largest Market | North America |
Market Overview
Global Urinary Tract Infection Therapeutics Market has valued at USD 7.20 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 3.12% through 2028.
UTIs are one of the most common bacterial infections, affecting millions of individuals worldwide. The high incidence of UTIs drives demand for effective treatment options.
Key Market Drivers
Advancements in Diagnostics
Advancements in diagnostics for urinary tract infections (UTIs) have the potential to improve patient outcomes by enabling more accurate and timely diagnosis, leading to appropriate and targeted treatment.
Microfluidic platforms are being developed to automate and miniaturize diagnostic processes. These devices can analyze urine samples for the presence of bacteria and biomarkers quickly and efficiently. Mass spectrometry-based techniques are being explored for identifying bacterial pathogens and detecting antimicrobial resistance. These methods can provide detailed information about the infecting organisms. Advances in culture techniques, such as automated systems, can speed up the identification of bacterial species causing UTIs and provide information about antibiotic susceptibility. Imaging techniques like ultrasound and computed tomography (CT) scans can help visualize the urinary tract and identify structural abnormalities that might contribute to recurrent UTIs. Endoscopic procedures that allow visualization of the urinary tract can help identify anatomical abnormalities, stones, or other factors contributing to UTIs. Artificial intelligence and machine learning algorithms can analyze large datasets to identify patterns and predict UTI outcomes based on patient history, symptoms, and test results. Metabolomics involves analyzing the metabolites present in urine samples. This approach can provide insights into the host-microbe interaction during UTIs and potentially lead to new diagnostic markers. Researchers are exploring non-invasive methods for UTI diagnosis, such as analyzing urine odor or using sensor-based technologies to detect bacterial presence. This factor will help in the development of
Growing Aging Population
Aging is associated with a decline in the immune system's function, making older adults more susceptible to infections, including UTIs. A weakened immune response can result in a higher incidence of infections and a greater need for appropriate treatment. Older individuals often have underlying health conditions such as diabetes, kidney disease, and urinary incontinence. These conditions can increase the risk of UTIs and make them more challenging to manage, requiring specialized therapeutics. Anatomical changes in the urinary tract, including weakened bladder muscles and reduced bladder capacity, can contribute to UTIs in older adults. These changes may necessitate tailored treatment approaches. Older adults may have a higher likelihood of requiring urinary catheters, which increases the risk of catheter associated UTIs. Effective therapeutics are crucial to managing and preventing these infections. Older adults may be more susceptible to UTIs during hospital stays or in long-term care settings. Effective treatments are essential to prevent complications and improve patient outcomes.
Increasing Antibiotic Resistance Concerns
Antibiotic resistance occurs when bacteria evolve to resist the effects of antibiotics, rendering traditional treatments ineffective. As antibiotic resistance increases, the range of effective antibiotics for treating UTIs becomes narrower, emphasizing the need for new and alternative therapeutic options. UTIs that are caused by antibiotic-resistant bacteria are harder to treat with conventional antibiotics. This can lead to treatment failures, prolonged infections, and a higher risk of complications. Antibiotic-resistant UTIs are more likely to recur, as bacteria that survive antibiotic treatment can lead to relapses. Effective UTI therapeutics are vital to prevent recurrent infections and break the cycle of resistance. In healthcare settings, patients with antibiotic resistant UTIs can experience longer hospital stays, increased healthcare costs, and a higher risk of adverse outcomes. Effective therapeutics are crucial to managing and preventing these infections. Resistant bacteria can spread within communities, increasing the risk of acquiring antibiotic resistant UTIs. This spread highlights the urgency of developing and using effective therapies to curb the proliferation of resistance.
Antibiotic resistance is a global public health concern. Infections that were once easily treatable may become life-threatening due to the lack of effective antibiotics. Developing new UTI therapeutics is part of the broader effort to combat antibiotic resistance. The increased healthcare costs associated with treating antibiotic-resistant infections, including UTIs, can strain healthcare systems and burden both patients and societies. Effective therapeutics can help mitigate these economic challenges. Governments, healthcare organizations, and international bodies are focusing on addressing antibiotic resistance through awareness campaigns, surveillance programs, and research efforts. These initiatives underscore the importance of developing effective UTI therapeutics. The urgency of antibiotic resistance has spurred research into new drug classes, alternative treatments, and combination therapies. Pharmaceutical companies are investing in the development of innovative therapeutics to combat resistant UTIs. Healthcare providers are increasingly practicing antibiotic stewardship to promote responsible antibiotic use. Developing effective UTI therapeutics that are less likely to contribute to resistance aligns with these stewardship principles. The complexity of antibiotic resistance patterns calls for personalized treatment strategies. Effective UTI therapeutics need to address specific bacterial strains and resistance mechanisms. This factor will accelerate the demand of
Key Market Challenges
Emergence of Virulent Strains
Virulent strains of bacteria can exhibit higher levels of resistance to antibiotics, rendering conventional treatments less effective. This can lead to prolonged infections, increased healthcare utilization, and a higher risk of complications. Virulent strains often cause more severe infections with more pronounced symptoms. Patients infected with such strains may experience more discomfort and require more aggressive treatment strategies. UTIs caused by virulent strains can be associated with a higher risk of complications, including kidney infections (pyelonephritis) and bloodstream infections (bacteremia), which can be life-threatening if not promptly treated. Hospitals and healthcare settings can be reservoirs for virulent bacterial strains. UTIs acquired in healthcare settings often involve more resistant and virulent strains, necessitating specialized therapeutics and infection control measures. The emergence of drug-resistant and virulent strains can limit the found at treatment options for UTIs. Healthcare providers may need to rely on more powerful antibiotics, combination therapies, or alternative treatment approaches.
Limited New Drug Development
The rise of antibiotic-resistant bacteria is a pressing concern. Limited new drug development contributes to a shortage of effective antibiotics against resistant strains, making it difficult to treat certain UTIs. The absence of new drugs can lead to treatment failures, prolonged infections, and recurrent UTIs. This can result in patient discomfort, increased healthcare utilization, and higher costs. With few new drugs entering the market, healthcare providers may have limited options to choose from. This could lead to over-reliance on a small set of antibiotics, potentially exacerbating resistance issues. The lack of new drug development can lead to economic consequences, including increased healthcare costs due to extended treatment periods and hospitalizations for severe cases. A lack of innovation hinders the discovery of novel treatment approaches, leaving patients with fewer alternatives to traditional antibiotics. The aging population and increased healthcare demand mean that UTI treatment requirements are on the rise. New drugs are crucial to meet this growing demand. Limited potential for profit from developing new UTI drugs might discourage pharmaceutical companies from investing in research and development efforts.
Key Market Trends
Antibiotic Stewardship
Antibiotic stewardship refers to the coordinated efforts to promote the responsible and judicious use of antibiotics to prevent the development of antibiotic resistance, improve patient outcomes, and optimize healthcare resources. Antibiotic stewardship programs aim to ensure that antibiotics are prescribed only when necessary and appropriate. This approach helps prevent the overuse and misuse of antibiotics, preserving their effectiveness for future use. One of the primary goals of antibiotic stewardship is to combat the development of antibiotic resistance. By limiting unnecessary antibiotic use, the emergence and spread of resistant bacteria can be slowed down. Antibiotic stewardship encourages healthcare providers to explore alternative treatment options, such as non-antibiotic therapies, for managing UTIs when appropriate. Stewardship practices emphasize individualized treatment plans based on the patient's condition, the causative pathogen, and antibiotic susceptibility. This approach improves treatment outcomes and minimizes unnecessary exposure to antibiotics. Antibiotic stewardship programs involve educating healthcare professionals, patients, and the public about the importance of proper antibiotic use, the risks of resistance, and the benefits of responsible prescribing. Stewardship aligns with evidence-based guidelines for UTI treatment, ensuring that antibiotics are prescribed according to established best practices. Electronic health record systems and clinical decision support tools can assist healthcare providers in selecting appropriate antibiotics based on patient-specific factors and local resistance patterns.
Segmental Insights
Indication Insights
In 2022, the Global Urinary Tract Infection Therapeutics Market dominated by complicated UTI segment in the forecast period and is predicted to continue expanding over the coming years.
Drug Insights
In 2022, the Global Urinary Tract Infection Therapeutics Market dominated by quinolones drugs segment and is predicted to continue expanding over the coming years.
Regional Insights
The North America region dominates the Global Urinary Tract Infection Therapeutics Market in 2022. The region boasts well-developed healthcare infrastructure, including hospitals, clinics, research institutions, and pharmaceutical companies. This infrastructure facilitates the research, development, and distribution of UTI therapeutics.
Recent Developments
- In September 2021, Biapenemwas launched and made available to patients with intra-abdominal infections,lower respiratory infections, or difficult urinary tract infections, accordingto BDR Pharma, one of India's top generic pharmaceutical businesses. With therelease of biapenem under the trade name Biapen on the market, BDR Pharmaraises the bar for its extensive line of critical care segment medicines. Thefirst company to recognize and develop this product was BDR Pharma, which alsoco-sponsored clinical trials with some of the industry's top competitors in thecritical care market. Additionally, BDR Pharma was the first to receive thismedication's DCGI (Drug Controller General of India) approval. Patients withserious urinary tract infections, intraabdominal infections, or lowerrespiratory infections typically receive biapenem prescriptions. It belongs toa class of essential parenteral carbapenem antibiotic. Biapen's dosage isconsiderably lower than that of the current generation of carbapenems,nevertheless.
- In October 2021, The U.S. Food and Drug Administration (FDA) hasreceived a new drug application (NDA) for tebipenem HBr tablets to treatcomplicated urinary tract infections (cUTI), including pyelonephritis. SperoTherapeutics Inc., a multi-asset clinical-stage biopharmaceutical companyfocused on identifying, developing, and commercialising treatments in highunmet need areas involving multi-drug resistant bacterial infections and rarediseases, Tebipenem HBr would be the only oral carbapenem antibiotic offeredfor use in cUTI if it were authorised.
Key Market Players
- AstraZenecaPLC.
- Bayer AG
- Cipla Inc.
- GlaxoSmithKlinePLC
- Shionogi& Co. Ltd
- NovartisAG
- PfizerInc.
- Merck& Co. Inc
- Bristol-MyersSquibb Company
- AlmirallSA
- AllerganInc.
| By Drug | By Indication | By Region |
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy